M&A Deal Summary

Aldevron Acquires Intergalactic

On April 23, 2024, Aldevron acquired life science company Intergalactic

Acquisition Highlights
  • This is Aldevron’s 2nd transaction in the Life Science sector.
  • This is Aldevron’s 1st transaction in the United States.
  • This is Aldevron’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2024-04-23
Target Intergalactic
Sector Life Science
Buyer(s) Aldevron
Deal Type Special Situations/Distressed
Advisor(s) Cassel Salpeter & Co. (Financial)

Target

Intergalactic

Cambridge, Massachusetts, United States
website
Intergalactic is a developer of non-viral gene therapies initially targeting ophthalmic diseases. The company is focused on overcoming the limitations of gene transfer by combining synthetic biology and precision engineering. Their technology platform enables the broad application of non-viral gene therapies by developing tunable, persistent, and safe non-viral DNA in vivo. Intergalactic is based in Cambridge, Massachusetts.

Search 193,103 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aldevron

Fargo, North Dakota, United States

website

Category Company
Founded 1998
Sector Life Science
DESCRIPTION

Aldevron serves the biotechnology industry with the custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA, and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron was founded in 1998 and is based in Fargo, North Dakota.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Special Situations/Distressed) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-01 Genovac

Freiburg, Germany

Genovac is a contract research and manufacturing organization offering advanced antibody discovery solutions. Its immunization technologies, combined with multiple single-cell screening technologies, including Berkeley Lights’ Beacon, enable success against the most challenging targets. Genovac was founded in 1999 and is based in Freiburg, Germany.

Sell -
Mergr

Product

Company

Legal